Skip to main content


Fig. 3 | Cardiovascular Diabetology

Fig. 3

From: Comparative outcomes of heart failure among existent classes of anti-diabetic agents: a network meta-analysis of 171,253 participants from 91 randomized controlled trials

Fig. 3

Mixed comparisons of anti-diabetic agents for heart failure by drug class. Agents are reported in order of heart failure risk ranking. Treatment at the top left corner ranks first, while the one at the bottom right corner ranks last. An odds ratio (OR) lower than 1 indicates better safety for heart failurein favor of the column-defining treatment. SGLT2i sodium-glucoseco-transporter 2 inhibitors, GLP1ra glucagon-like peptide-1 receptor agonists, DPP4i dipeptidyl peptidase 4 inhibitors, TZD thiazolidinediones, MET metformin, SU sulfonylureas, INS insulin, PLA placebo

Back to article page